Medivir AB
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Medivir AB
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.
/ 
Frequently asked questions
To buy Medivir AB stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Medivir AB by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Medivir AB is MVIR:xome. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Medivir AB has its primary listing on NASDAQ OMX Stockholm. You can trade Medivir AB with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Medivir AB is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Medivir AB as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Medivir AB.